Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Prostatic Neoplasms | 249 | 2024 | 11097 | 11.170 |
Why?
|
Prostatectomy | 76 | 2024 | 1786 | 6.530 |
Why?
|
Urinary Bladder Neoplasms | 74 | 2024 | 2186 | 5.450 |
Why?
|
Cystectomy | 50 | 2024 | 603 | 5.100 |
Why?
|
Prostate-Specific Antigen | 63 | 2024 | 2463 | 4.020 |
Why?
|
Prostate | 31 | 2024 | 1761 | 2.600 |
Why?
|
Androgen Antagonists | 28 | 2024 | 1412 | 2.340 |
Why?
|
Kidney Neoplasms | 34 | 2023 | 4282 | 2.080 |
Why?
|
Carcinoma, Transitional Cell | 13 | 2021 | 790 | 1.780 |
Why?
|
Nephrectomy | 25 | 2022 | 928 | 1.740 |
Why?
|
Genetic Predisposition to Disease | 46 | 2024 | 18063 | 1.390 |
Why?
|
Male | 383 | 2024 | 364203 | 1.360 |
Why?
|
Laparoscopy | 23 | 2023 | 2037 | 1.270 |
Why?
|
Early Detection of Cancer | 25 | 2024 | 3236 | 1.260 |
Why?
|
Carcinoma, Renal Cell | 21 | 2023 | 3186 | 1.190 |
Why?
|
Polymorphism, Single Nucleotide | 45 | 2024 | 16036 | 1.160 |
Why?
|
Physicians, Primary Care | 2 | 2024 | 623 | 1.130 |
Why?
|
Antineoplastic Agents, Hormonal | 12 | 2023 | 1536 | 1.120 |
Why?
|
Neoplasm Staging | 45 | 2024 | 11217 | 1.090 |
Why?
|
Neoplasms, Hormone-Dependent | 4 | 2018 | 409 | 1.040 |
Why?
|
Aged | 223 | 2024 | 171319 | 1.040 |
Why?
|
Robotics | 15 | 2023 | 807 | 1.020 |
Why?
|
Phenylthiohydantoin | 5 | 2021 | 206 | 0.970 |
Why?
|
Humans | 422 | 2024 | 767040 | 0.970 |
Why?
|
Lymph Node Excision | 16 | 2024 | 1267 | 0.960 |
Why?
|
Biopsy | 13 | 2024 | 6777 | 0.910 |
Why?
|
Orchiectomy | 6 | 2016 | 466 | 0.890 |
Why?
|
Kallikreins | 10 | 2021 | 219 | 0.870 |
Why?
|
Postoperative Complications | 43 | 2023 | 15824 | 0.860 |
Why?
|
Middle Aged | 207 | 2024 | 223233 | 0.860 |
Why?
|
DNA Repair-Deficiency Disorders | 1 | 2021 | 37 | 0.760 |
Why?
|
Urologic Neoplasms | 6 | 2017 | 312 | 0.760 |
Why?
|
SEER Program | 16 | 2024 | 1444 | 0.750 |
Why?
|
Ureteral Neoplasms | 2 | 2021 | 106 | 0.720 |
Why?
|
Brachytherapy | 7 | 2018 | 1220 | 0.710 |
Why?
|
Multifactorial Inheritance | 8 | 2024 | 1422 | 0.690 |
Why?
|
Germ-Line Mutation | 9 | 2024 | 1885 | 0.690 |
Why?
|
Birt-Hogg-Dube Syndrome | 1 | 2020 | 40 | 0.690 |
Why?
|
Neoplasm Recurrence, Local | 20 | 2024 | 9410 | 0.690 |
Why?
|
Neoadjuvant Therapy | 15 | 2024 | 2902 | 0.690 |
Why?
|
DNA Repair | 6 | 2023 | 2050 | 0.690 |
Why?
|
Receptors, Androgen | 8 | 2021 | 1089 | 0.660 |
Why?
|
Urology | 5 | 2020 | 384 | 0.660 |
Why?
|
Watchful Waiting | 6 | 2024 | 492 | 0.650 |
Why?
|
Healthcare Disparities | 12 | 2024 | 3414 | 0.640 |
Why?
|
Tissue Extracts | 4 | 2022 | 139 | 0.600 |
Why?
|
United States | 91 | 2024 | 72971 | 0.560 |
Why?
|
Polymorphism, Genetic | 5 | 2016 | 4247 | 0.550 |
Why?
|
Leuprolide | 6 | 2024 | 313 | 0.540 |
Why?
|
Poultry | 1 | 2016 | 79 | 0.540 |
Why?
|
Urothelium | 3 | 2017 | 275 | 0.540 |
Why?
|
Androgen Receptor Antagonists | 2 | 2014 | 123 | 0.540 |
Why?
|
Risk Assessment | 43 | 2024 | 24299 | 0.530 |
Why?
|
Cancer Vaccines | 2 | 2022 | 1041 | 0.530 |
Why?
|
Chromosomes, Human, Pair 12 | 4 | 2004 | 432 | 0.530 |
Why?
|
Urogenital Neoplasms | 2 | 2009 | 130 | 0.530 |
Why?
|
Carcinoma | 7 | 2010 | 2326 | 0.520 |
Why?
|
Disease Management | 3 | 2017 | 2531 | 0.520 |
Why?
|
Genome-Wide Association Study | 31 | 2024 | 12790 | 0.510 |
Why?
|
Medical Oncology | 6 | 2020 | 2341 | 0.510 |
Why?
|
Risk Factors | 67 | 2024 | 74886 | 0.500 |
Why?
|
Cell Cycle Proteins | 5 | 2016 | 3440 | 0.500 |
Why?
|
Retrospective Studies | 80 | 2024 | 81659 | 0.500 |
Why?
|
Lymphatic Metastasis | 10 | 2024 | 2900 | 0.500 |
Why?
|
Eggs | 1 | 2016 | 182 | 0.490 |
Why?
|
Aged, 80 and over | 66 | 2024 | 59548 | 0.480 |
Why?
|
Treatment Outcome | 67 | 2024 | 65295 | 0.480 |
Why?
|
Hospitals | 11 | 2024 | 3883 | 0.480 |
Why?
|
DNA, Neoplasm | 3 | 2013 | 1741 | 0.470 |
Why?
|
Nomograms | 3 | 2014 | 236 | 0.450 |
Why?
|
Receptors, Calcium-Sensing | 1 | 2015 | 320 | 0.450 |
Why?
|
Tumor Burden | 4 | 2019 | 1903 | 0.440 |
Why?
|
BCG Vaccine | 3 | 2023 | 381 | 0.440 |
Why?
|
Chemotherapy, Adjuvant | 18 | 2024 | 3552 | 0.440 |
Why?
|
Chromosome Deletion | 3 | 2004 | 1384 | 0.430 |
Why?
|
Urinary Incontinence | 4 | 2024 | 490 | 0.430 |
Why?
|
Chromosome Mapping | 10 | 2018 | 4616 | 0.420 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 14 | 2020 | 11872 | 0.420 |
Why?
|
Fishes | 1 | 2016 | 607 | 0.420 |
Why?
|
Neoplasm Invasiveness | 16 | 2024 | 3611 | 0.420 |
Why?
|
Mass Screening | 12 | 2024 | 5456 | 0.420 |
Why?
|
Survival Rate | 24 | 2021 | 12823 | 0.420 |
Why?
|
Antineoplastic Agents | 10 | 2024 | 13650 | 0.420 |
Why?
|
Mandelic Acids | 1 | 2012 | 46 | 0.410 |
Why?
|
Androgens | 8 | 2024 | 1281 | 0.410 |
Why?
|
Urologic Surgical Procedures | 4 | 2016 | 281 | 0.400 |
Why?
|
Surgery, Computer-Assisted | 4 | 2013 | 996 | 0.390 |
Why?
|
Kaplan-Meier Estimate | 15 | 2024 | 6513 | 0.390 |
Why?
|
Muscarinic Antagonists | 1 | 2012 | 135 | 0.390 |
Why?
|
Genetic Loci | 7 | 2021 | 2629 | 0.390 |
Why?
|
Erectile Dysfunction | 4 | 2023 | 437 | 0.390 |
Why?
|
MicroRNAs | 6 | 2020 | 3792 | 0.380 |
Why?
|
Venous Thromboembolism | 6 | 2020 | 1883 | 0.380 |
Why?
|
Prospective Studies | 45 | 2024 | 54886 | 0.380 |
Why?
|
Chromosomes, Human, Pair 8 | 3 | 2021 | 451 | 0.370 |
Why?
|
Prognosis | 34 | 2024 | 29963 | 0.370 |
Why?
|
Disease-Free Survival | 17 | 2024 | 6844 | 0.370 |
Why?
|
Urinary Diversion | 3 | 2017 | 134 | 0.360 |
Why?
|
Lung Diseases | 2 | 2020 | 1942 | 0.360 |
Why?
|
Adenocarcinoma | 8 | 2019 | 6360 | 0.360 |
Why?
|
Tumor Suppressor Proteins | 6 | 2016 | 2800 | 0.360 |
Why?
|
Medicare | 11 | 2023 | 6813 | 0.360 |
Why?
|
Proportional Hazards Models | 22 | 2024 | 12536 | 0.360 |
Why?
|
Pelvic Neoplasms | 2 | 2020 | 249 | 0.350 |
Why?
|
Genes, cdc | 2 | 2008 | 113 | 0.350 |
Why?
|
Testicular Neoplasms | 5 | 2016 | 806 | 0.340 |
Why?
|
Patient Readmission | 12 | 2019 | 3283 | 0.340 |
Why?
|
Magnetic Resonance Imaging | 13 | 2024 | 36582 | 0.340 |
Why?
|
Caspase 8 | 1 | 2010 | 198 | 0.330 |
Why?
|
Adult | 82 | 2024 | 223317 | 0.330 |
Why?
|
Length of Stay | 19 | 2020 | 6489 | 0.320 |
Why?
|
Biopsy, Needle | 2 | 2012 | 1615 | 0.320 |
Why?
|
Genotype | 21 | 2021 | 13035 | 0.320 |
Why?
|
Taxoids | 4 | 2017 | 665 | 0.320 |
Why?
|
Neoplasm Metastasis | 12 | 2023 | 4892 | 0.310 |
Why?
|
Case-Control Studies | 30 | 2022 | 22254 | 0.310 |
Why?
|
Androstenes | 2 | 2021 | 177 | 0.310 |
Why?
|
Magnetic Resonance Imaging, Interventional | 2 | 2024 | 195 | 0.310 |
Why?
|
Kidney Pelvis | 3 | 2019 | 191 | 0.300 |
Why?
|
Homeodomain Proteins | 3 | 2022 | 2429 | 0.300 |
Why?
|
Female | 118 | 2024 | 396660 | 0.300 |
Why?
|
Databases, Factual | 22 | 2020 | 8068 | 0.300 |
Why?
|
Salvage Therapy | 3 | 2023 | 1271 | 0.290 |
Why?
|
Follow-Up Studies | 33 | 2024 | 39317 | 0.290 |
Why?
|
Muscle Neoplasms | 2 | 2019 | 130 | 0.290 |
Why?
|
Colectomy | 4 | 2020 | 696 | 0.290 |
Why?
|
Vena Cava, Inferior | 2 | 2003 | 463 | 0.280 |
Why?
|
Urinary Bladder | 8 | 2023 | 1155 | 0.280 |
Why?
|
Adjuvants, Immunologic | 1 | 2012 | 998 | 0.280 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2022 | 3249 | 0.280 |
Why?
|
Germ Cells | 5 | 2023 | 644 | 0.280 |
Why?
|
Gene Expression Regulation, Neoplastic | 12 | 2019 | 8628 | 0.280 |
Why?
|
Health Care Costs | 6 | 2020 | 3239 | 0.280 |
Why?
|
Health Expenditures | 7 | 2023 | 2390 | 0.280 |
Why?
|
Genetic Variation | 10 | 2020 | 6611 | 0.280 |
Why?
|
Cell Movement | 3 | 2018 | 5203 | 0.270 |
Why?
|
Logistic Models | 17 | 2023 | 13284 | 0.260 |
Why?
|
Matrix Metalloproteinase 9 | 1 | 2009 | 633 | 0.260 |
Why?
|
Quality of Life | 13 | 2024 | 13485 | 0.260 |
Why?
|
Vietnam Conflict | 2 | 2024 | 100 | 0.260 |
Why?
|
Health Services Accessibility | 6 | 2023 | 5519 | 0.260 |
Why?
|
Poly(ADP-ribose) Polymerases | 2 | 2019 | 428 | 0.260 |
Why?
|
Incidence | 23 | 2023 | 21526 | 0.260 |
Why?
|
Clinical Medicine | 1 | 2007 | 145 | 0.260 |
Why?
|
Survival Analysis | 17 | 2021 | 10092 | 0.260 |
Why?
|
Genes, BRCA2 | 5 | 2023 | 591 | 0.260 |
Why?
|
Chromosomes, Human, Pair 13 | 2 | 2017 | 192 | 0.250 |
Why?
|
Smoking | 7 | 2024 | 9081 | 0.250 |
Why?
|
Hysterectomy | 3 | 2020 | 863 | 0.250 |
Why?
|
Immunotherapy | 5 | 2022 | 4745 | 0.250 |
Why?
|
Predictive Value of Tests | 13 | 2024 | 15424 | 0.250 |
Why?
|
Hospital Costs | 6 | 2022 | 956 | 0.250 |
Why?
|
Inheritance Patterns | 2 | 2019 | 344 | 0.250 |
Why?
|
Nitriles | 5 | 2021 | 980 | 0.240 |
Why?
|
Disease Susceptibility | 2 | 2018 | 1791 | 0.240 |
Why?
|
Age Factors | 13 | 2022 | 18401 | 0.240 |
Why?
|
Postoperative Care | 1 | 2011 | 1480 | 0.240 |
Why?
|
Combined Modality Therapy | 12 | 2021 | 8535 | 0.240 |
Why?
|
Prednisone | 4 | 2024 | 1566 | 0.240 |
Why?
|
Muscles | 5 | 2021 | 1576 | 0.240 |
Why?
|
DNA-Binding Proteins | 4 | 2016 | 9612 | 0.240 |
Why?
|
Multivariate Analysis | 16 | 2021 | 12069 | 0.240 |
Why?
|
Ultrasonography, Interventional | 3 | 2024 | 1523 | 0.240 |
Why?
|
Time Factors | 27 | 2024 | 40154 | 0.230 |
Why?
|
Neoplasms | 11 | 2024 | 22350 | 0.230 |
Why?
|
Acute Kidney Injury | 4 | 2020 | 1946 | 0.230 |
Why?
|
Loss of Heterozygosity | 3 | 2004 | 663 | 0.230 |
Why?
|
Urology Department, Hospital | 1 | 2003 | 1 | 0.230 |
Why?
|
Surgical Procedures, Operative | 4 | 2016 | 1931 | 0.230 |
Why?
|
Gene Frequency | 6 | 2024 | 3621 | 0.230 |
Why?
|
Proto-Oncogene Proteins | 1 | 2016 | 4522 | 0.220 |
Why?
|
Odds Ratio | 14 | 2021 | 9660 | 0.220 |
Why?
|
Neoplasms, Germ Cell and Embryonal | 2 | 2016 | 498 | 0.220 |
Why?
|
Hematuria | 1 | 2005 | 232 | 0.220 |
Why?
|
Cyclins | 2 | 2003 | 605 | 0.220 |
Why?
|
Calcium | 2 | 2015 | 5792 | 0.210 |
Why?
|
Insurance, Health | 3 | 2020 | 2519 | 0.210 |
Why?
|
Genes, Tumor Suppressor | 5 | 2008 | 1058 | 0.210 |
Why?
|
Cohort Studies | 23 | 2024 | 41718 | 0.210 |
Why?
|
Medicaid | 5 | 2023 | 2836 | 0.210 |
Why?
|
Hospitalization | 6 | 2019 | 10815 | 0.210 |
Why?
|
Polycystic Kidney, Autosomal Dominant | 1 | 2004 | 166 | 0.210 |
Why?
|
Epistasis, Genetic | 3 | 2024 | 353 | 0.210 |
Why?
|
Comparative Effectiveness Research | 5 | 2018 | 713 | 0.210 |
Why?
|
Veterans | 5 | 2024 | 2666 | 0.210 |
Why?
|
Disease Progression | 11 | 2021 | 13646 | 0.200 |
Why?
|
Breast Neoplasms | 11 | 2024 | 21178 | 0.200 |
Why?
|
Mendelian Randomization Analysis | 6 | 2018 | 1040 | 0.200 |
Why?
|
Neoplastic Cells, Circulating | 2 | 2001 | 949 | 0.200 |
Why?
|
Gonadotropin-Releasing Hormone | 3 | 2018 | 1149 | 0.200 |
Why?
|
Laser Therapy | 2 | 2023 | 1108 | 0.200 |
Why?
|
Benzamides | 4 | 2021 | 1376 | 0.200 |
Why?
|
Radiotherapy, Adjuvant | 4 | 2023 | 1788 | 0.190 |
Why?
|
Absenteeism | 2 | 2020 | 247 | 0.190 |
Why?
|
Registries | 7 | 2023 | 8351 | 0.190 |
Why?
|
Lung Neoplasms | 8 | 2024 | 13491 | 0.190 |
Why?
|
Genetic Testing | 2 | 2023 | 3591 | 0.190 |
Why?
|
Convalescence | 2 | 2020 | 107 | 0.190 |
Why?
|
Thiohydantoins | 1 | 2021 | 19 | 0.190 |
Why?
|
Blood Transfusion | 5 | 2020 | 1308 | 0.190 |
Why?
|
Germinoma | 1 | 2002 | 132 | 0.190 |
Why?
|
DNA Mutational Analysis | 2 | 2016 | 4114 | 0.180 |
Why?
|
Cryptorchidism | 1 | 2002 | 153 | 0.180 |
Why?
|
Hypercalcemia | 1 | 2004 | 424 | 0.180 |
Why?
|
5-alpha Reductase Inhibitors | 1 | 2022 | 112 | 0.180 |
Why?
|
Antineoplastic Protocols | 1 | 2020 | 48 | 0.180 |
Why?
|
Diet | 3 | 2024 | 8089 | 0.180 |
Why?
|
Prostatic Hyperplasia | 2 | 2015 | 514 | 0.180 |
Why?
|
Colonic Neoplasms | 2 | 2024 | 2535 | 0.180 |
Why?
|
Lower Gastrointestinal Tract | 1 | 2020 | 13 | 0.180 |
Why?
|
Access to Information | 1 | 2023 | 317 | 0.180 |
Why?
|
Patient Protection and Affordable Care Act | 5 | 2023 | 1188 | 0.180 |
Why?
|
Peripheral Arterial Disease | 1 | 2012 | 1304 | 0.180 |
Why?
|
Insurance Coverage | 3 | 2021 | 1945 | 0.170 |
Why?
|
Risk | 11 | 2018 | 9606 | 0.170 |
Why?
|
Ligases | 3 | 1997 | 330 | 0.170 |
Why?
|
Rhabdomyolysis | 2 | 2015 | 150 | 0.170 |
Why?
|
Ileus | 1 | 2020 | 65 | 0.170 |
Why?
|
Thromboembolism | 2 | 1997 | 1003 | 0.170 |
Why?
|
X Chromosome | 1 | 2003 | 819 | 0.170 |
Why?
|
Motor Activity | 1 | 2009 | 2713 | 0.170 |
Why?
|
Insulin Resistance | 2 | 2024 | 3986 | 0.160 |
Why?
|
Retroperitoneal Space | 2 | 2011 | 175 | 0.160 |
Why?
|
Receptors, Calcitriol | 2 | 1999 | 361 | 0.160 |
Why?
|
Urologic Diseases | 2 | 2007 | 246 | 0.160 |
Why?
|
Comorbidity | 8 | 2018 | 10582 | 0.160 |
Why?
|
Fanconi Anemia | 1 | 2021 | 327 | 0.160 |
Why?
|
Hepatocyte Nuclear Factor 3-alpha | 1 | 2019 | 165 | 0.160 |
Why?
|
Neoplasm Proteins | 3 | 2019 | 3599 | 0.160 |
Why?
|
S Phase | 1 | 2000 | 424 | 0.160 |
Why?
|
G1 Phase | 1 | 2000 | 403 | 0.160 |
Why?
|
Models, Genetic | 4 | 2024 | 3445 | 0.150 |
Why?
|
DNA Mismatch Repair | 1 | 2021 | 431 | 0.150 |
Why?
|
Macrophage Migration-Inhibitory Factors | 1 | 2018 | 109 | 0.150 |
Why?
|
Hemangioma | 1 | 2003 | 727 | 0.150 |
Why?
|
Receptors, CXCR | 1 | 2018 | 52 | 0.150 |
Why?
|
Kidney Calculi | 1 | 2023 | 458 | 0.150 |
Why?
|
Intramolecular Oxidoreductases | 1 | 2018 | 105 | 0.150 |
Why?
|
Minority Health | 1 | 2019 | 79 | 0.150 |
Why?
|
Testosterone | 5 | 2024 | 2490 | 0.150 |
Why?
|
Antigens, Neoplasm | 2 | 2017 | 1997 | 0.150 |
Why?
|
Guideline Adherence | 2 | 2019 | 2232 | 0.150 |
Why?
|
Cell Line, Tumor | 10 | 2019 | 17097 | 0.150 |
Why?
|
Feasibility Studies | 3 | 2024 | 5311 | 0.150 |
Why?
|
Penile Diseases | 1 | 1998 | 47 | 0.150 |
Why?
|
Pelvis | 3 | 2019 | 736 | 0.150 |
Why?
|
Minority Groups | 3 | 2024 | 1214 | 0.150 |
Why?
|
Hyperinsulinism | 1 | 2021 | 402 | 0.150 |
Why?
|
Genetic Markers | 4 | 2018 | 2602 | 0.150 |
Why?
|
Marital Status | 1 | 2019 | 426 | 0.150 |
Why?
|
Quality Improvement | 8 | 2016 | 3854 | 0.140 |
Why?
|
Acetates | 2 | 2013 | 314 | 0.140 |
Why?
|
Antineoplastic Agents, Alkylating | 1 | 2021 | 614 | 0.140 |
Why?
|
Patient Acceptance of Health Care | 3 | 2020 | 3232 | 0.140 |
Why?
|
Travel | 1 | 2023 | 805 | 0.140 |
Why?
|
Down-Regulation | 3 | 2017 | 2931 | 0.140 |
Why?
|
Decision Making | 2 | 2024 | 3951 | 0.140 |
Why?
|
Quality of Health Care | 4 | 2020 | 4306 | 0.140 |
Why?
|
Positron-Emission Tomography | 2 | 2013 | 6550 | 0.140 |
Why?
|
BRCA1 Protein | 3 | 2023 | 1155 | 0.140 |
Why?
|
Propensity Score | 7 | 2020 | 1971 | 0.140 |
Why?
|
Retinal Dehydrogenase | 1 | 2016 | 78 | 0.130 |
Why?
|
Pilot Projects | 3 | 2024 | 8732 | 0.130 |
Why?
|
Patient Care | 1 | 2022 | 628 | 0.130 |
Why?
|
Testicular Hydrocele | 1 | 2016 | 27 | 0.130 |
Why?
|
Gene Deletion | 1 | 2004 | 2668 | 0.130 |
Why?
|
Cost of Illness | 5 | 2023 | 1951 | 0.130 |
Why?
|
DNA Primers | 3 | 2006 | 2827 | 0.130 |
Why?
|
Secretory Leukocyte Peptidase Inhibitor | 1 | 2016 | 23 | 0.130 |
Why?
|
Cryosurgery | 3 | 2006 | 479 | 0.130 |
Why?
|
Receptors, Immunologic | 2 | 2020 | 1418 | 0.130 |
Why?
|
Carcinoma, Papillary | 1 | 2021 | 791 | 0.130 |
Why?
|
Bone Neoplasms | 4 | 2014 | 2563 | 0.130 |
Why?
|
Sequence Deletion | 2 | 2008 | 1494 | 0.130 |
Why?
|
Aldehyde Dehydrogenase | 1 | 2016 | 146 | 0.130 |
Why?
|
BRCA2 Protein | 2 | 2022 | 802 | 0.130 |
Why?
|
Pain Perception | 1 | 2017 | 198 | 0.130 |
Why?
|
Somatomedins | 1 | 2016 | 179 | 0.130 |
Why?
|
Hypoalbuminemia | 1 | 2016 | 90 | 0.130 |
Why?
|
Analgesics, Opioid | 3 | 2020 | 3837 | 0.130 |
Why?
|
Colorectal Neoplasms | 7 | 2020 | 6966 | 0.130 |
Why?
|
Osteoporotic Fractures | 1 | 2020 | 417 | 0.120 |
Why?
|
Kidney | 6 | 2023 | 7063 | 0.120 |
Why?
|
Analgesics, Non-Narcotic | 1 | 2019 | 370 | 0.120 |
Why?
|
Administration, Intravesical | 2 | 2012 | 88 | 0.120 |
Why?
|
Cyclophosphamide | 1 | 2021 | 2227 | 0.120 |
Why?
|
Internship and Residency | 4 | 2016 | 5947 | 0.120 |
Why?
|
Ubiquitin-Protein Ligases | 4 | 2022 | 1900 | 0.120 |
Why?
|
Insulin-Like Growth Factor Binding Proteins | 1 | 2016 | 208 | 0.120 |
Why?
|
Missouri | 3 | 2018 | 113 | 0.120 |
Why?
|
Carbon | 2 | 2013 | 672 | 0.120 |
Why?
|
Urethral Stricture | 1 | 2015 | 50 | 0.120 |
Why?
|
Tomography, X-Ray Computed | 3 | 2021 | 20741 | 0.120 |
Why?
|
Leukocytes, Mononuclear | 1 | 2022 | 1854 | 0.120 |
Why?
|
Exercise | 2 | 2024 | 5954 | 0.120 |
Why?
|
Dementia | 2 | 2019 | 2741 | 0.120 |
Why?
|
Heart Atria | 1 | 2001 | 1362 | 0.120 |
Why?
|
Pain, Postoperative | 3 | 2020 | 1768 | 0.120 |
Why?
|
Acetaminophen | 1 | 2019 | 549 | 0.120 |
Why?
|
Regression Analysis | 5 | 2020 | 6331 | 0.120 |
Why?
|
Erythropoiesis | 1 | 2018 | 691 | 0.120 |
Why?
|
Drug Administration Schedule | 3 | 2014 | 4855 | 0.120 |
Why?
|
Accidents | 1 | 2015 | 164 | 0.120 |
Why?
|
Neoplasms, Radiation-Induced | 1 | 2018 | 542 | 0.120 |
Why?
|
Primary Health Care | 2 | 2024 | 4746 | 0.110 |
Why?
|
Sexual Maturation | 1 | 2016 | 258 | 0.110 |
Why?
|
Vegetables | 1 | 2020 | 1199 | 0.110 |
Why?
|
Clinical Trials as Topic | 8 | 2020 | 8048 | 0.110 |
Why?
|
Urinary Bladder Diseases | 1 | 1995 | 166 | 0.110 |
Why?
|
Carboplatin | 1 | 2017 | 790 | 0.110 |
Why?
|
Statistics as Topic | 2 | 2018 | 2350 | 0.110 |
Why?
|
Insurance Benefits | 1 | 2016 | 185 | 0.110 |
Why?
|
Erythropoietin | 1 | 2018 | 718 | 0.110 |
Why?
|
Dioxygenases | 1 | 2016 | 353 | 0.110 |
Why?
|
Cardiovascular Surgical Procedures | 1 | 2015 | 193 | 0.110 |
Why?
|
Kidney Diseases | 1 | 2005 | 2099 | 0.110 |
Why?
|
Randomized Controlled Trials as Topic | 6 | 2022 | 10393 | 0.110 |
Why?
|
Suicide | 2 | 2015 | 1606 | 0.110 |
Why?
|
Radiosurgery | 1 | 2023 | 1330 | 0.110 |
Why?
|
Preventive Health Services | 1 | 2018 | 570 | 0.110 |
Why?
|
Software | 2 | 2018 | 4472 | 0.110 |
Why?
|
Workplace | 1 | 2020 | 873 | 0.110 |
Why?
|
Chromosomes, Human, Pair 17 | 2 | 2014 | 418 | 0.110 |
Why?
|
Pharmaceutical Preparations | 1 | 2021 | 1085 | 0.110 |
Why?
|
Linkage Disequilibrium | 5 | 2016 | 1996 | 0.110 |
Why?
|
Sample Size | 2 | 2020 | 845 | 0.110 |
Why?
|
Urolithiasis | 1 | 2015 | 123 | 0.110 |
Why?
|
Chi-Square Distribution | 3 | 2018 | 3431 | 0.110 |
Why?
|
Transurethral Resection of Prostate | 1 | 2014 | 77 | 0.110 |
Why?
|
Ovarian Neoplasms | 4 | 2019 | 4903 | 0.110 |
Why?
|
Decision Support Techniques | 2 | 2014 | 2006 | 0.110 |
Why?
|
Mortality | 3 | 2020 | 2909 | 0.110 |
Why?
|
Capillaries | 1 | 2016 | 755 | 0.110 |
Why?
|
Nuclear Proteins | 3 | 2018 | 5794 | 0.110 |
Why?
|
Fatty Acids, Unsaturated | 1 | 2016 | 541 | 0.110 |
Why?
|
Ureteral Obstruction | 1 | 2015 | 293 | 0.110 |
Why?
|
Palliative Care | 3 | 2021 | 3641 | 0.110 |
Why?
|
Genetic Association Studies | 3 | 2017 | 2744 | 0.110 |
Why?
|
Protective Agents | 1 | 2014 | 150 | 0.110 |
Why?
|
Muscle, Smooth | 1 | 2017 | 930 | 0.100 |
Why?
|
Clinical Trials, Phase III as Topic | 3 | 2022 | 878 | 0.100 |
Why?
|
Intestinal Obstruction | 1 | 2016 | 433 | 0.100 |
Why?
|
Anticoagulants | 2 | 2019 | 4854 | 0.100 |
Why?
|
Cell Proliferation | 6 | 2018 | 10455 | 0.100 |
Why?
|
Forecasting | 3 | 2017 | 2936 | 0.100 |
Why?
|
Anemia | 1 | 2022 | 1514 | 0.100 |
Why?
|
Young Adult | 16 | 2021 | 59980 | 0.100 |
Why?
|
Aftercare | 1 | 2018 | 915 | 0.100 |
Why?
|
Fee-for-Service Plans | 1 | 2017 | 713 | 0.100 |
Why?
|
Organ Size | 2 | 2007 | 2264 | 0.100 |
Why?
|
Coffee | 1 | 2016 | 594 | 0.100 |
Why?
|
Puerperal Disorders | 1 | 1995 | 304 | 0.100 |
Why?
|
Warfarin | 2 | 1997 | 1493 | 0.100 |
Why?
|
Hospital Charges | 1 | 2013 | 345 | 0.100 |
Why?
|
Counseling | 1 | 2020 | 1553 | 0.100 |
Why?
|
Defoliants, Chemical | 2 | 2024 | 9 | 0.100 |
Why?
|
Antibiotic Prophylaxis | 1 | 2017 | 640 | 0.100 |
Why?
|
Urinary Tract Infections | 2 | 2015 | 804 | 0.100 |
Why?
|
Age of Onset | 3 | 2018 | 3344 | 0.100 |
Why?
|
Smoking Cessation | 1 | 2023 | 2085 | 0.100 |
Why?
|
Chromosomes, Human, Pair 5 | 1 | 2013 | 386 | 0.100 |
Why?
|
Drug Resistance, Neoplasm | 4 | 2023 | 5332 | 0.090 |
Why?
|
Cyclin-Dependent Kinase Inhibitor p27 | 2 | 2003 | 317 | 0.090 |
Why?
|
Repressor Proteins | 1 | 2002 | 2979 | 0.090 |
Why?
|
Metabolome | 1 | 2018 | 1008 | 0.090 |
Why?
|
Penile Erection | 1 | 2011 | 100 | 0.090 |
Why?
|
Reoperation | 2 | 2019 | 4325 | 0.090 |
Why?
|
Piperidines | 1 | 2020 | 1667 | 0.090 |
Why?
|
Granulocyte Colony-Stimulating Factor | 1 | 2014 | 631 | 0.090 |
Why?
|
Health Status Disparities | 1 | 2023 | 1882 | 0.090 |
Why?
|
Inpatients | 2 | 2013 | 2563 | 0.090 |
Why?
|
Metabolomics | 1 | 2020 | 1675 | 0.090 |
Why?
|
DNA Damage | 1 | 2021 | 2469 | 0.090 |
Why?
|
T-Lymphocytes, Cytotoxic | 1 | 2018 | 1801 | 0.090 |
Why?
|
Diffusion Tensor Imaging | 1 | 2021 | 2421 | 0.090 |
Why?
|
Ischemia | 1 | 2020 | 1905 | 0.090 |
Why?
|
DNA Methylation | 2 | 2004 | 4426 | 0.090 |
Why?
|
Angina Pectoris | 1 | 2015 | 956 | 0.090 |
Why?
|
Osteoporosis | 1 | 2020 | 1604 | 0.090 |
Why?
|
Transplantation, Heterologous | 3 | 2004 | 2391 | 0.090 |
Why?
|
Necrosis | 2 | 2010 | 1614 | 0.090 |
Why?
|
Body Mass Index | 3 | 2024 | 13048 | 0.090 |
Why?
|
Intestine, Small | 1 | 2016 | 1217 | 0.090 |
Why?
|
Cancer Care Facilities | 3 | 2018 | 427 | 0.090 |
Why?
|
Double-Blind Method | 4 | 2021 | 12451 | 0.090 |
Why?
|
Patient Discharge | 2 | 2023 | 3467 | 0.090 |
Why?
|
Alleles | 7 | 2016 | 6893 | 0.080 |
Why?
|
Proto-Oncogene Proteins c-akt | 1 | 2018 | 2457 | 0.080 |
Why?
|
Eating | 1 | 2016 | 1541 | 0.080 |
Why?
|
Nerve Tissue Proteins | 2 | 2020 | 4401 | 0.080 |
Why?
|
Rectal Neoplasms | 1 | 2018 | 1183 | 0.080 |
Why?
|
Spinal Fusion | 1 | 2019 | 1307 | 0.080 |
Why?
|
Mice, SCID | 3 | 2018 | 2626 | 0.080 |
Why?
|
Practice Guidelines as Topic | 5 | 2024 | 7435 | 0.080 |
Why?
|
Adolescent | 16 | 2020 | 89046 | 0.080 |
Why?
|
Societies, Medical | 4 | 2020 | 3964 | 0.080 |
Why?
|
Oncogene Proteins, Fusion | 1 | 2017 | 1608 | 0.080 |
Why?
|
Body Height | 1 | 2015 | 1565 | 0.080 |
Why?
|
25-Hydroxyvitamin D3 1-alpha-Hydroxylase | 1 | 2009 | 57 | 0.080 |
Why?
|
Health Status Indicators | 1 | 2014 | 969 | 0.080 |
Why?
|
Tumor Cells, Cultured | 4 | 2002 | 6106 | 0.080 |
Why?
|
Thyroid Neoplasms | 1 | 2022 | 2355 | 0.080 |
Why?
|
Polymerase Chain Reaction | 4 | 2003 | 6067 | 0.080 |
Why?
|
Treatment Failure | 3 | 2014 | 2658 | 0.080 |
Why?
|
Steroid Hydroxylases | 1 | 2009 | 93 | 0.080 |
Why?
|
Europe | 4 | 2021 | 3432 | 0.080 |
Why?
|
Cross-Sectional Studies | 7 | 2023 | 26325 | 0.080 |
Why?
|
Random Allocation | 3 | 2018 | 2394 | 0.080 |
Why?
|
Lymph Nodes | 4 | 2017 | 3468 | 0.080 |
Why?
|
Delayed-Action Preparations | 1 | 2012 | 965 | 0.080 |
Why?
|
Health Knowledge, Attitudes, Practice | 1 | 2023 | 4054 | 0.080 |
Why?
|
Coronary Artery Bypass | 1 | 1998 | 2189 | 0.080 |
Why?
|
Blood Chemical Analysis | 1 | 2010 | 434 | 0.080 |
Why?
|
Obesity | 2 | 2015 | 13085 | 0.080 |
Why?
|
Arthroplasty, Replacement, Hip | 1 | 2019 | 1417 | 0.080 |
Why?
|
Surgical Wound Infection | 2 | 2015 | 1547 | 0.080 |
Why?
|
Arthroplasty, Replacement, Knee | 1 | 2019 | 1389 | 0.080 |
Why?
|
Models, Statistical | 2 | 2021 | 5098 | 0.080 |
Why?
|
Learning Curve | 1 | 2010 | 232 | 0.080 |
Why?
|
beta Catenin | 1 | 2013 | 1048 | 0.070 |
Why?
|
Adenoma, Oxyphilic | 1 | 2009 | 151 | 0.070 |
Why?
|
Calcifediol | 1 | 2009 | 160 | 0.070 |
Why?
|
RNA, Small Nucleolar | 1 | 2008 | 27 | 0.070 |
Why?
|
Health Status | 3 | 2018 | 4091 | 0.070 |
Why?
|
Stem Cell Transplantation | 1 | 2016 | 1596 | 0.070 |
Why?
|
Quality Indicators, Health Care | 2 | 2016 | 1804 | 0.070 |
Why?
|
Hospice Care | 1 | 2015 | 678 | 0.070 |
Why?
|
Telomerase | 1 | 2013 | 751 | 0.070 |
Why?
|
Cholestenone 5 alpha-Reductase | 1 | 2007 | 21 | 0.070 |
Why?
|
Ablation Techniques | 2 | 2020 | 255 | 0.070 |
Why?
|
Patient Admission | 1 | 2015 | 1364 | 0.070 |
Why?
|
Phenotype | 3 | 2019 | 16718 | 0.070 |
Why?
|
RNA | 1 | 2017 | 2715 | 0.070 |
Why?
|
Calcitriol | 1 | 2009 | 303 | 0.070 |
Why?
|
Genomics | 2 | 2021 | 5924 | 0.070 |
Why?
|
Longitudinal Studies | 6 | 2024 | 14766 | 0.070 |
Why?
|
Molecular Sequence Annotation | 2 | 2021 | 526 | 0.070 |
Why?
|
Animals | 15 | 2021 | 168965 | 0.070 |
Why?
|
Interdisciplinary Communication | 1 | 2013 | 935 | 0.070 |
Why?
|
Sequence Analysis, DNA | 3 | 2021 | 4780 | 0.070 |
Why?
|
Preoperative Care | 2 | 2009 | 2252 | 0.070 |
Why?
|
Chromosomes, Human, Pair 6 | 1 | 2008 | 370 | 0.070 |
Why?
|
Ureter | 2 | 2015 | 364 | 0.070 |
Why?
|
Electronic Health Records | 1 | 2024 | 4881 | 0.070 |
Why?
|
Binding Sites | 1 | 2015 | 6014 | 0.070 |
Why?
|
DNA | 2 | 2016 | 7210 | 0.060 |
Why?
|
Cystoscopy | 2 | 2015 | 128 | 0.060 |
Why?
|
RNA, Messenger | 3 | 2018 | 12793 | 0.060 |
Why?
|
Universities | 1 | 2011 | 1004 | 0.060 |
Why?
|
Meta-Analysis as Topic | 3 | 2016 | 1364 | 0.060 |
Why?
|
Self Report | 4 | 2021 | 3773 | 0.060 |
Why?
|
Gene Expression Profiling | 3 | 2017 | 9532 | 0.060 |
Why?
|
Scavenger Receptors, Class A | 1 | 2006 | 52 | 0.060 |
Why?
|
Preoperative Period | 2 | 2021 | 564 | 0.060 |
Why?
|
Estramustine | 1 | 2005 | 35 | 0.060 |
Why?
|
Sensitivity and Specificity | 5 | 2013 | 14672 | 0.060 |
Why?
|
Nephrons | 1 | 2006 | 165 | 0.060 |
Why?
|
Wound Healing | 1 | 2016 | 2800 | 0.060 |
Why?
|
Mitoxantrone | 1 | 2005 | 148 | 0.060 |
Why?
|
Radiation-Sensitizing Agents | 1 | 2007 | 348 | 0.060 |
Why?
|
Orthopedic Procedures | 1 | 2015 | 1279 | 0.060 |
Why?
|
Tosyl Compounds | 1 | 2005 | 115 | 0.060 |
Why?
|
Lipids | 1 | 2016 | 3322 | 0.060 |
Why?
|
Mutation | 5 | 2016 | 30211 | 0.060 |
Why?
|
Postoperative Period | 2 | 2020 | 1824 | 0.060 |
Why?
|
2,4,5-Trichlorophenoxyacetic Acid | 1 | 2024 | 15 | 0.060 |
Why?
|
Consensus | 3 | 2020 | 3207 | 0.060 |
Why?
|
Medically Uninsured | 2 | 2020 | 838 | 0.060 |
Why?
|
2,4-Dichlorophenoxyacetic Acid | 1 | 2024 | 24 | 0.060 |
Why?
|
Mice | 10 | 2020 | 81912 | 0.060 |
Why?
|
Head and Neck Neoplasms | 1 | 2019 | 2930 | 0.060 |
Why?
|
Perioperative Period | 2 | 2016 | 252 | 0.060 |
Why?
|
Probability | 2 | 2023 | 2476 | 0.060 |
Why?
|
Behavioral Risk Factor Surveillance System | 2 | 2016 | 212 | 0.060 |
Why?
|
Urinary Tract | 1 | 2007 | 305 | 0.060 |
Why?
|
Patient-Centered Care | 1 | 2014 | 1444 | 0.060 |
Why?
|
von Hippel-Lindau Disease | 2 | 1995 | 154 | 0.060 |
Why?
|
Overweight | 1 | 2015 | 2448 | 0.060 |
Why?
|
Delivery of Health Care | 2 | 2022 | 5363 | 0.060 |
Why?
|
Quantitative Trait Loci | 3 | 2018 | 2131 | 0.060 |
Why?
|
Endoribonucleases | 1 | 2006 | 231 | 0.060 |
Why?
|
Diffusion Magnetic Resonance Imaging | 2 | 2021 | 2811 | 0.060 |
Why?
|
Adjuvants, Pharmaceutic | 1 | 2023 | 48 | 0.060 |
Why?
|
Cost Savings | 2 | 2019 | 904 | 0.060 |
Why?
|
Alcohol Drinking | 1 | 2016 | 4045 | 0.050 |
Why?
|
Glucocorticoids | 1 | 2013 | 2163 | 0.050 |
Why?
|
Stem Cells | 1 | 2016 | 3535 | 0.050 |
Why?
|
Rectum | 1 | 2008 | 898 | 0.050 |
Why?
|
Laparoscopes | 1 | 2003 | 36 | 0.050 |
Why?
|
Terminal Care | 1 | 2015 | 1770 | 0.050 |
Why?
|
Patient Selection | 2 | 2012 | 4256 | 0.050 |
Why?
|
Cluster Analysis | 2 | 2024 | 2721 | 0.050 |
Why?
|
Kidney Calices | 1 | 2023 | 26 | 0.050 |
Why?
|
Anxiety | 2 | 2017 | 4670 | 0.050 |
Why?
|
Ureteroscopes | 1 | 2023 | 22 | 0.050 |
Why?
|
Telemedicine | 1 | 2020 | 3110 | 0.050 |
Why?
|
Education, Medical, Graduate | 1 | 2015 | 2420 | 0.050 |
Why?
|
Recurrence | 3 | 2011 | 8504 | 0.050 |
Why?
|
Fluorodeoxyglucose F18 | 2 | 2009 | 2028 | 0.050 |
Why?
|
Neoplasm, Residual | 2 | 2019 | 1012 | 0.050 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 2 | 2013 | 4572 | 0.050 |
Why?
|
Epigenesis, Genetic | 1 | 2016 | 3828 | 0.050 |
Why?
|
Polymorphism, Single-Stranded Conformational | 1 | 2002 | 325 | 0.050 |
Why?
|
Academic Medical Centers | 1 | 2013 | 2783 | 0.050 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 1 | 2021 | 5389 | 0.050 |
Why?
|
Environmental Exposure | 1 | 2017 | 4546 | 0.050 |
Why?
|
Heart Diseases | 1 | 2015 | 2817 | 0.050 |
Why?
|
Hemostatic Techniques | 1 | 2003 | 116 | 0.050 |
Why?
|
Anilides | 1 | 2005 | 413 | 0.050 |
Why?
|
Hemostasis, Surgical | 1 | 2002 | 128 | 0.050 |
Why?
|
Electrocoagulation | 1 | 2002 | 156 | 0.050 |
Why?
|
Ribonuclease H | 1 | 2022 | 52 | 0.050 |
Why?
|
Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2003 | 376 | 0.050 |
Why?
|
Hospitals, University | 1 | 2003 | 570 | 0.050 |
Why?
|
Energy Metabolism | 1 | 2013 | 2906 | 0.050 |
Why?
|
Depressive Disorder | 1 | 2014 | 3721 | 0.050 |
Why?
|
Life Style | 2 | 2024 | 3931 | 0.050 |
Why?
|
Retinoblastoma Binding Proteins | 1 | 2022 | 101 | 0.050 |
Why?
|
Ureteroscopy | 1 | 2023 | 139 | 0.050 |
Why?
|
Proto-Oncogene Proteins c-ets | 1 | 2002 | 313 | 0.050 |
Why?
|
Ultrasonography | 3 | 2012 | 6000 | 0.050 |
Why?
|
Depression | 2 | 2019 | 8234 | 0.050 |
Why?
|
Reproducibility of Results | 4 | 2013 | 20169 | 0.050 |
Why?
|
Multicenter Studies as Topic | 2 | 2017 | 1733 | 0.050 |
Why?
|
Sweden | 1 | 2024 | 1382 | 0.050 |
Why?
|
Socioeconomic Factors | 3 | 2020 | 7848 | 0.050 |
Why?
|
Early Diagnosis | 1 | 2006 | 1188 | 0.050 |
Why?
|
Melanoma | 1 | 2019 | 5702 | 0.050 |
Why?
|
Carcinoma, Squamous Cell | 1 | 1996 | 4049 | 0.050 |
Why?
|
Sepsis | 1 | 2015 | 2605 | 0.040 |
Why?
|
Population Control | 1 | 2020 | 23 | 0.040 |
Why?
|
Image Interpretation, Computer-Assisted | 2 | 2014 | 3370 | 0.040 |
Why?
|
Algorithms | 4 | 2018 | 14098 | 0.040 |
Why?
|
Xenograft Model Antitumor Assays | 2 | 2019 | 3608 | 0.040 |
Why?
|
Costs and Cost Analysis | 2 | 2017 | 1666 | 0.040 |
Why?
|
Hospitals, Teaching | 2 | 2017 | 1156 | 0.040 |
Why?
|
Life Expectancy | 2 | 2019 | 1248 | 0.040 |
Why?
|
Morbidity | 2 | 2017 | 1754 | 0.040 |
Why?
|
Tomography, Emission-Computed | 1 | 2003 | 1007 | 0.040 |
Why?
|
Inflammatory Bowel Diseases | 1 | 2015 | 2441 | 0.040 |
Why?
|
Diaphragm | 1 | 2002 | 357 | 0.040 |
Why?
|
Renal Insufficiency, Chronic | 1 | 2014 | 2299 | 0.040 |
Why?
|
American Cancer Society | 1 | 2019 | 69 | 0.040 |
Why?
|
Von Hippel-Lindau Tumor Suppressor Protein | 3 | 1997 | 304 | 0.040 |
Why?
|
Incidental Findings | 1 | 2005 | 698 | 0.040 |
Why?
|
Recombinant Fusion Proteins | 3 | 2018 | 3738 | 0.040 |
Why?
|
Base Sequence | 3 | 2008 | 12414 | 0.040 |
Why?
|
Contig Mapping | 1 | 1999 | 56 | 0.040 |
Why?
|
RNA, Double-Stranded | 1 | 2021 | 292 | 0.040 |
Why?
|
Models, Theoretical | 1 | 2011 | 3561 | 0.040 |
Why?
|
Transfection | 2 | 2018 | 5753 | 0.040 |
Why?
|
Deoxyribonucleases, Type II Site-Specific | 1 | 1999 | 167 | 0.040 |
Why?
|
Urinary Calculi | 1 | 1999 | 81 | 0.040 |
Why?
|
Ambulatory Surgical Procedures | 1 | 2023 | 452 | 0.040 |
Why?
|
Single-Blind Method | 2 | 2018 | 1587 | 0.040 |
Why?
|
Lysosomal-Associated Membrane Protein 1 | 1 | 2018 | 25 | 0.040 |
Why?
|
Southeastern United States | 1 | 2018 | 93 | 0.040 |
Why?
|
Histological Techniques | 1 | 2019 | 193 | 0.040 |
Why?
|
Evidence-Based Medicine | 2 | 2020 | 3700 | 0.040 |
Why?
|
Erythrocyte Count | 1 | 2018 | 157 | 0.040 |
Why?
|
Pneumothorax | 1 | 2002 | 393 | 0.040 |
Why?
|
Hospital Mortality | 3 | 2019 | 5345 | 0.040 |
Why?
|
Acid Phosphatase | 1 | 2018 | 141 | 0.040 |
Why?
|
Colon | 3 | 2021 | 1797 | 0.040 |
Why?
|
Anti-Bacterial Agents | 1 | 2017 | 7469 | 0.040 |
Why?
|
Education, Medical, Continuing | 1 | 2003 | 829 | 0.040 |
Why?
|
Blotting, Southern | 1 | 1998 | 775 | 0.040 |
Why?
|
Anisotropy | 1 | 2021 | 1289 | 0.040 |
Why?
|
Prescriptions | 1 | 2020 | 388 | 0.040 |
Why?
|
Mice, Inbred ICR | 1 | 2018 | 361 | 0.040 |
Why?
|
Apoptosis | 2 | 2013 | 9513 | 0.040 |
Why?
|
Ribonuclease III | 1 | 2020 | 271 | 0.040 |
Why?
|
Gene Amplification | 1 | 2002 | 1088 | 0.040 |
Why?
|
Prevalence | 2 | 2016 | 15851 | 0.040 |
Why?
|
Tissue Array Analysis | 1 | 2019 | 545 | 0.040 |
Why?
|
Matrix Metalloproteinase 16 | 1 | 2017 | 4 | 0.040 |
Why?
|
Blood Loss, Surgical | 3 | 2010 | 642 | 0.040 |
Why?
|
Ribs | 1 | 1999 | 257 | 0.040 |
Why?
|
Disease Models, Animal | 4 | 2020 | 18330 | 0.040 |
Why?
|
Perception | 1 | 2024 | 1205 | 0.040 |
Why?
|
Climate Change | 1 | 2024 | 509 | 0.040 |
Why?
|
Interferons | 1 | 2021 | 716 | 0.030 |
Why?
|
Cell Transformation, Neoplastic | 2 | 1998 | 2843 | 0.030 |
Why?
|
Survivors | 2 | 2023 | 2381 | 0.030 |
Why?
|
DEAD-box RNA Helicases | 1 | 2020 | 385 | 0.030 |
Why?
|
Workflow | 1 | 2021 | 859 | 0.030 |
Why?
|
Signal Transduction | 5 | 2019 | 23621 | 0.030 |
Why?
|
Phthalazines | 1 | 2019 | 397 | 0.030 |
Why?
|
Chromosomes, Human, Pair 22 | 1 | 2017 | 348 | 0.030 |
Why?
|
Cyclin-Dependent Kinases | 1 | 2000 | 661 | 0.030 |
Why?
|
Retinoblastoma Protein | 1 | 2000 | 670 | 0.030 |
Why?
|
Surgical Wound Dehiscence | 1 | 2017 | 215 | 0.030 |
Why?
|
Telephone | 1 | 2020 | 629 | 0.030 |
Why?
|
Histones | 2 | 2017 | 2597 | 0.030 |
Why?
|
Gene Knockout Techniques | 1 | 2019 | 804 | 0.030 |
Why?
|
Drug Therapy, Combination | 2 | 2021 | 6310 | 0.030 |
Why?
|
CD8-Positive T-Lymphocytes | 2 | 2021 | 4648 | 0.030 |
Why?
|
Transcription Factors | 1 | 1995 | 12158 | 0.030 |
Why?
|
Cooperative Behavior | 2 | 2013 | 1512 | 0.030 |
Why?
|
Ferritins | 1 | 2018 | 601 | 0.030 |
Why?
|
Radiation Injuries | 2 | 2014 | 1196 | 0.030 |
Why?
|
Microvessels | 1 | 2020 | 585 | 0.030 |
Why?
|
Cost Sharing | 1 | 2019 | 409 | 0.030 |
Why?
|
Patient Satisfaction | 1 | 2008 | 3488 | 0.030 |
Why?
|
Insulin Receptor Substrate Proteins | 1 | 2017 | 558 | 0.030 |
Why?
|
Vitamin D | 1 | 2009 | 3312 | 0.030 |
Why?
|
Uterine Cervical Neoplasms | 2 | 2018 | 2038 | 0.030 |
Why?
|
Urinalysis | 1 | 2017 | 369 | 0.030 |
Why?
|
Gastrointestinal Agents | 1 | 2020 | 511 | 0.030 |
Why?
|
Analysis of Variance | 2 | 2014 | 6215 | 0.030 |
Why?
|
Gene Expression | 2 | 2018 | 7587 | 0.030 |
Why?
|
Income | 1 | 2024 | 1877 | 0.030 |
Why?
|
R-SNARE Proteins | 1 | 2015 | 73 | 0.030 |
Why?
|
Gene Silencing | 1 | 2001 | 1505 | 0.030 |
Why?
|
Teratoma | 1 | 1998 | 405 | 0.030 |
Why?
|
Neoplasm Transplantation | 1 | 1998 | 2012 | 0.030 |
Why?
|
Renal Artery | 1 | 2016 | 355 | 0.030 |
Why?
|
Prostheses and Implants | 1 | 2021 | 1275 | 0.030 |
Why?
|
Physicians | 1 | 2013 | 4593 | 0.030 |
Why?
|
Phospholipids | 1 | 2018 | 778 | 0.030 |
Why?
|
DNA Replication | 1 | 2022 | 1426 | 0.030 |
Why?
|
Oligonucleotide Array Sequence Analysis | 2 | 2013 | 3797 | 0.030 |
Why?
|
Atlases as Topic | 1 | 2016 | 247 | 0.030 |
Why?
|
Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2018 | 892 | 0.030 |
Why?
|
Body Composition | 1 | 2024 | 2454 | 0.030 |
Why?
|
Radiotherapy Planning, Computer-Assisted | 1 | 2023 | 1677 | 0.030 |
Why?
|
Language | 1 | 2024 | 1550 | 0.030 |
Why?
|
Laparotomy | 1 | 2016 | 459 | 0.030 |
Why?
|
Antigens, CD34 | 1 | 2016 | 655 | 0.030 |
Why?
|
Filgrastim | 1 | 2014 | 131 | 0.030 |
Why?
|
DNA Repair Enzymes | 1 | 2016 | 342 | 0.030 |
Why?
|
Rupture, Spontaneous | 1 | 1995 | 365 | 0.030 |
Why?
|
Direct Service Costs | 1 | 2014 | 61 | 0.030 |
Why?
|
Benzimidazoles | 1 | 2019 | 862 | 0.030 |
Why?
|
Patients | 1 | 2020 | 908 | 0.030 |
Why?
|
Equipment and Supplies, Hospital | 1 | 2014 | 55 | 0.030 |
Why?
|
Endothelium | 1 | 2016 | 768 | 0.030 |
Why?
|
Ohio | 1 | 2014 | 321 | 0.030 |
Why?
|
Peritoneum | 1 | 1995 | 227 | 0.030 |
Why?
|
Myocardial Infarction | 1 | 2015 | 11513 | 0.030 |
Why?
|
Vascular Endothelial Growth Factor Receptor-2 | 1 | 2016 | 547 | 0.030 |
Why?
|
Demography | 1 | 2018 | 1641 | 0.030 |
Why?
|
Peptide Fragments | 1 | 2006 | 5141 | 0.030 |
Why?
|
Cost-Benefit Analysis | 2 | 2020 | 5537 | 0.030 |
Why?
|
Pain Threshold | 1 | 2017 | 607 | 0.030 |
Why?
|
Pandemics | 2 | 2023 | 8736 | 0.030 |
Why?
|
Bandages | 1 | 1995 | 271 | 0.030 |
Why?
|
Magnetic Resonance Spectroscopy | 1 | 2023 | 3684 | 0.030 |
Why?
|
Acetylation | 1 | 2016 | 1055 | 0.030 |
Why?
|
Sex Factors | 2 | 2019 | 10622 | 0.030 |
Why?
|
Dextrans | 1 | 1995 | 574 | 0.030 |
Why?
|
Perineum | 1 | 2014 | 212 | 0.030 |
Why?
|
Urethra | 1 | 2015 | 406 | 0.030 |
Why?
|
Quantitative Trait, Heritable | 1 | 2016 | 539 | 0.030 |
Why?
|
Hydrogen Peroxide | 1 | 2016 | 740 | 0.030 |
Why?
|
Diagnostic Tests, Routine | 1 | 2018 | 788 | 0.030 |
Why?
|
International Agencies | 1 | 2013 | 244 | 0.030 |
Why?
|
Vinblastine | 1 | 2014 | 482 | 0.030 |
Why?
|
3' Untranslated Regions | 1 | 2015 | 515 | 0.030 |
Why?
|
Puberty | 1 | 2016 | 501 | 0.030 |
Why?
|
Fluorescent Antibody Technique | 2 | 2013 | 2472 | 0.030 |
Why?
|
Digital Rectal Examination | 1 | 2012 | 42 | 0.030 |
Why?
|
Coculture Techniques | 1 | 2016 | 1337 | 0.030 |
Why?
|
Hematocrit | 1 | 2014 | 622 | 0.030 |
Why?
|
Health Care Surveys | 1 | 2019 | 2428 | 0.020 |
Why?
|
Haplotypes | 1 | 2018 | 2722 | 0.020 |
Why?
|
Area Under Curve | 1 | 2016 | 1639 | 0.020 |
Why?
|
Exosomes | 1 | 2016 | 417 | 0.020 |
Why?
|
Receptors, CXCR4 | 1 | 2016 | 729 | 0.020 |
Why?
|
Luciferases | 1 | 2013 | 713 | 0.020 |
Why?
|
Molecular Sequence Data | 3 | 2008 | 17608 | 0.020 |
Why?
|
National Cancer Institute (U.S.) | 1 | 2013 | 300 | 0.020 |
Why?
|
Organ Specificity | 1 | 2016 | 1966 | 0.020 |
Why?
|
Transplantation, Autologous | 1 | 2016 | 2118 | 0.020 |
Why?
|
Republic of Korea | 1 | 2013 | 591 | 0.020 |
Why?
|
Endonucleases | 1 | 2014 | 371 | 0.020 |
Why?
|
Proteins | 2 | 1997 | 6001 | 0.020 |
Why?
|
Gadolinium DTPA | 1 | 2014 | 823 | 0.020 |
Why?
|
Drug Prescriptions | 1 | 2020 | 1664 | 0.020 |
Why?
|
International Cooperation | 1 | 2017 | 1434 | 0.020 |
Why?
|
Office Visits | 1 | 2015 | 595 | 0.020 |
Why?
|
Asia | 1 | 2013 | 629 | 0.020 |
Why?
|
Washington | 1 | 2011 | 315 | 0.020 |
Why?
|
Colonoscopy | 1 | 2019 | 1409 | 0.020 |
Why?
|
Appendectomy | 1 | 2014 | 444 | 0.020 |
Why?
|
Creatinine | 1 | 2016 | 1916 | 0.020 |
Why?
|
Triglycerides | 1 | 2018 | 2444 | 0.020 |
Why?
|
Serum Albumin | 1 | 2014 | 676 | 0.020 |
Why?
|
Perioperative Care | 1 | 2018 | 1043 | 0.020 |
Why?
|
Liver | 2 | 2024 | 7578 | 0.020 |
Why?
|
Drug Delivery Systems | 1 | 2021 | 2212 | 0.020 |
Why?
|
Delphi Technique | 1 | 2014 | 891 | 0.020 |
Why?
|
Point Mutation | 1 | 1995 | 1591 | 0.020 |
Why?
|
RNA, Small Interfering | 1 | 2019 | 3427 | 0.020 |
Why?
|
Australia | 1 | 2014 | 1263 | 0.020 |
Why?
|
Clinical Laboratory Techniques | 1 | 2015 | 746 | 0.020 |
Why?
|
Bayes Theorem | 1 | 2018 | 2353 | 0.020 |
Why?
|
Transcriptional Activation | 1 | 2016 | 1751 | 0.020 |
Why?
|
Recovery of Function | 1 | 2020 | 2978 | 0.020 |
Why?
|
Radiotherapy Dosage | 1 | 2016 | 2915 | 0.020 |
Why?
|
Diffusion of Innovation | 1 | 2014 | 724 | 0.020 |
Why?
|
Enhancer Elements, Genetic | 1 | 2016 | 1366 | 0.020 |
Why?
|
Cholesterol | 1 | 2018 | 2905 | 0.020 |
Why?
|
Lymphoma, Non-Hodgkin | 1 | 1997 | 1372 | 0.020 |
Why?
|
Epidemiologic Research Design | 1 | 2013 | 368 | 0.020 |
Why?
|
Cardiovascular Diseases | 1 | 2015 | 15645 | 0.020 |
Why?
|
Activities of Daily Living | 1 | 2018 | 2429 | 0.020 |
Why?
|
Tumor Suppressor Protein p53 | 1 | 2000 | 2952 | 0.020 |
Why?
|
Cell Cycle | 1 | 2017 | 2927 | 0.020 |
Why?
|
National Institutes of Health (U.S.) | 1 | 2013 | 793 | 0.020 |
Why?
|
History, 21st Century | 1 | 2015 | 1574 | 0.020 |
Why?
|
Social Support | 1 | 2019 | 2192 | 0.020 |
Why?
|
Muscle, Skeletal | 1 | 2024 | 4968 | 0.020 |
Why?
|
Gastrointestinal Diseases | 1 | 2017 | 1205 | 0.020 |
Why?
|
Up-Regulation | 1 | 2018 | 4143 | 0.020 |
Why?
|
Immunologic Factors | 1 | 2018 | 1592 | 0.020 |
Why?
|
RNA Interference | 1 | 2017 | 2829 | 0.020 |
Why?
|
Intercellular Signaling Peptides and Proteins | 1 | 2016 | 1655 | 0.020 |
Why?
|
Piperazines | 1 | 2019 | 2548 | 0.020 |
Why?
|
Immunohistochemistry | 3 | 2014 | 11063 | 0.020 |
Why?
|
Radiotherapy | 1 | 2015 | 1500 | 0.020 |
Why?
|
Health Surveys | 1 | 2018 | 4056 | 0.020 |
Why?
|
Polyethylene Glycols | 1 | 2014 | 1188 | 0.020 |
Why?
|
Pain Measurement | 1 | 2019 | 3584 | 0.020 |
Why?
|
ROC Curve | 1 | 2016 | 3618 | 0.020 |
Why?
|
Mammography | 1 | 2019 | 2431 | 0.020 |
Why?
|
Mental Health Services | 1 | 2019 | 1733 | 0.020 |
Why?
|
Cisplatin | 1 | 2014 | 1656 | 0.020 |
Why?
|
Military Personnel | 1 | 2017 | 1261 | 0.020 |
Why?
|
Environmental Pollutants | 1 | 2017 | 1296 | 0.020 |
Why?
|
Models, Economic | 1 | 2012 | 719 | 0.020 |
Why?
|
Heparin | 1 | 1995 | 1636 | 0.020 |
Why?
|
Gene Regulatory Networks | 1 | 2016 | 1752 | 0.020 |
Why?
|
Cardiopulmonary Resuscitation | 1 | 2015 | 996 | 0.020 |
Why?
|
Methotrexate | 1 | 2014 | 1718 | 0.020 |
Why?
|
Doxorubicin | 1 | 2014 | 2229 | 0.020 |
Why?
|
History, 20th Century | 1 | 2015 | 2765 | 0.020 |
Why?
|
Social Class | 1 | 2016 | 2007 | 0.020 |
Why?
|
Parenteral Nutrition | 1 | 2012 | 663 | 0.020 |
Why?
|
Molecular Targeted Therapy | 1 | 2018 | 2824 | 0.020 |
Why?
|
Amino Acid Sequence | 2 | 1995 | 13411 | 0.020 |
Why?
|
Urination Disorders | 1 | 2008 | 236 | 0.020 |
Why?
|
Kinetics | 1 | 2014 | 6287 | 0.020 |
Why?
|
Dissection | 1 | 2008 | 298 | 0.020 |
Why?
|
Computational Biology | 1 | 2018 | 3567 | 0.020 |
Why?
|
Models, Animal | 2 | 2003 | 2121 | 0.020 |
Why?
|
Epidemiologic Methods | 1 | 2011 | 1326 | 0.020 |
Why?
|
Cell Survival | 1 | 2016 | 5750 | 0.020 |
Why?
|
Blotting, Western | 1 | 2013 | 5022 | 0.020 |
Why?
|
Lymphocyte Activation | 1 | 2016 | 5499 | 0.020 |
Why?
|
Population Surveillance | 1 | 2016 | 2594 | 0.020 |
Why?
|
Adiposity | 1 | 2015 | 1894 | 0.020 |
Why?
|
Spouses | 1 | 2008 | 286 | 0.020 |
Why?
|
Medical Records | 1 | 2011 | 1409 | 0.020 |
Why?
|
Genes, Recessive | 1 | 2008 | 624 | 0.020 |
Why?
|
Computer Simulation | 1 | 2018 | 6260 | 0.020 |
Why?
|
Cause of Death | 1 | 2015 | 3717 | 0.010 |
Why?
|
Obesity, Morbid | 1 | 2015 | 1293 | 0.010 |
Why?
|
Recombinant Proteins | 1 | 2014 | 6507 | 0.010 |
Why?
|
Mice, Knockout | 1 | 2020 | 14476 | 0.010 |
Why?
|
Hemorrhage | 1 | 2016 | 3464 | 0.010 |
Why?
|
Infant, Newborn | 2 | 2015 | 26396 | 0.010 |
Why?
|
Aspirin | 1 | 1995 | 3135 | 0.010 |
Why?
|
Intestinal Diseases | 1 | 2008 | 505 | 0.010 |
Why?
|
Japan | 1 | 2007 | 1418 | 0.010 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2015 | 10748 | 0.010 |
Why?
|
Radiography | 1 | 2014 | 6975 | 0.010 |
Why?
|
Homozygote | 1 | 2008 | 1774 | 0.010 |
Why?
|
Swine | 2 | 2003 | 5987 | 0.010 |
Why?
|
Pneumoperitoneum, Artificial | 1 | 2002 | 42 | 0.010 |
Why?
|
Critical Care | 1 | 2015 | 2714 | 0.010 |
Why?
|
Lung | 1 | 2021 | 10076 | 0.010 |
Why?
|
Glomerular Filtration Rate | 1 | 2011 | 2227 | 0.010 |
Why?
|
Internationality | 1 | 2007 | 1006 | 0.010 |
Why?
|
Infant | 2 | 2015 | 36485 | 0.010 |
Why?
|
Promoter Regions, Genetic | 1 | 2013 | 5796 | 0.010 |
Why?
|
Cytoplasm | 2 | 1997 | 1504 | 0.010 |
Why?
|
Mice, Inbred C57BL | 1 | 2020 | 22361 | 0.010 |
Why?
|
Contrast Media | 1 | 2014 | 5329 | 0.010 |
Why?
|
Child, Preschool | 2 | 2015 | 42606 | 0.010 |
Why?
|
Inflammation | 1 | 2021 | 10869 | 0.010 |
Why?
|
Mice, Transgenic | 1 | 2013 | 9551 | 0.010 |
Why?
|
Surgical Instruments | 1 | 2002 | 381 | 0.010 |
Why?
|
Mental Health | 1 | 2014 | 3272 | 0.010 |
Why?
|
Models, Anatomic | 1 | 2003 | 679 | 0.010 |
Why?
|
Ileum | 1 | 2001 | 558 | 0.010 |
Why?
|
T-Lymphocytes | 1 | 2016 | 10254 | 0.010 |
Why?
|
Mental Disorders | 1 | 2019 | 6873 | 0.010 |
Why?
|
Calcium Oxalate | 1 | 1999 | 75 | 0.010 |
Why?
|
Image Enhancement | 1 | 2009 | 2867 | 0.010 |
Why?
|
Sexual Behavior | 1 | 2008 | 2196 | 0.010 |
Why?
|
Linear Models | 1 | 2008 | 5875 | 0.010 |
Why?
|
Pregnancy | 1 | 2019 | 30238 | 0.010 |
Why?
|
Carbon Dioxide | 1 | 2002 | 1137 | 0.010 |
Why?
|
Genome, Human | 1 | 2010 | 4441 | 0.010 |
Why?
|
Biomedical Research | 1 | 2013 | 3464 | 0.010 |
Why?
|
Research Design | 1 | 2013 | 6210 | 0.010 |
Why?
|
Child | 2 | 2015 | 80771 | 0.010 |
Why?
|
Intraoperative Complications | 1 | 2002 | 1171 | 0.010 |
Why?
|
Peptide Mapping | 1 | 1995 | 259 | 0.010 |
Why?
|
Mediastinal Neoplasms | 1 | 1998 | 403 | 0.010 |
Why?
|
Severity of Illness Index | 1 | 2013 | 15925 | 0.010 |
Why?
|
Cell Compartmentation | 1 | 1995 | 383 | 0.010 |
Why?
|
Clinical Competence | 1 | 2010 | 4859 | 0.010 |
Why?
|
Retroperitoneal Neoplasms | 1 | 1998 | 335 | 0.010 |
Why?
|
Blotting, Northern | 1 | 1995 | 1550 | 0.010 |
Why?
|
Testis | 1 | 1997 | 783 | 0.010 |
Why?
|
Radiopharmaceuticals | 1 | 2003 | 2702 | 0.010 |
Why?
|
Uterus | 1 | 1997 | 661 | 0.010 |
Why?
|
Tissue Distribution | 1 | 1997 | 2275 | 0.010 |
Why?
|
Epithelium | 1 | 1997 | 1606 | 0.010 |
Why?
|
Protein Biosynthesis | 1 | 1995 | 2093 | 0.000 |
Why?
|
Transcription, Genetic | 1 | 1995 | 7611 | 0.000 |
Why?
|